CytoDyn Welcomes Dr. Melissa Palmer as Lead Hepatology Consultant
CytoDyn Inc. (OTCQB: CYDY), a biotechnology firm based in Vancouver, Washington, specializes in developing innovative therapies, particularly leronlimab, which acts as a CCR5 antagonist. Recently, the company has appointed Dr. Melissa Palmer, M.D., to take on the role of Lead Consultant in Hepatology. Dr. Palmer's extensive experience positions her to steer CytoDyn's research and clinical efforts aimed at addressing liver diseases such as MASH and liver fibrosis.
Dr. Palmer's Role in Advancing Liver Disease Research
In her new role, Dr. Palmer's responsibilities will include guiding CytoDyn's strategic initiatives related to hepatic health. Her insights will be pivotal in optimizing the clinical research surrounding leronlimab, especially following exciting early findings from recent preclinical studies conducted in conjunction with SMC Laboratories. The engaging relationship with SMC has opened up avenues for CytoDyn to explore the potential of leronlimab in fibrotic conditions.
Follow-Up Studies in Collaboration with SMC Laboratories
Alongside her consulting duties, Dr. Palmer will oversee follow-up studies with SMC Laboratories aimed at validating the initial results indicating fibrosis reversal. These studies will involve comparing the efficacy of leronlimab both solo and in conjunction with existing therapies, notably with resmetirom and a GLP-1 agonist. CytoDyn aims to enhance its understanding of how these treatments can work together in specific animal models that simulate conditions such as MASH and liver fibrosis.
Dr. Palmer's Impressive Background
Dr. Palmer is a globally recognized hepatologist with over 30 years of research experience. Her career includes prominent leadership roles in various biotech firms, most notably as Chief Medical Officer at Gannex/Ascletis and head of liver disease at Takeda Pharmaceutical Company. She has contributed her expertise as a consultant for over 60 companies, nurturing advancements in liver disease research.
Significant Contributions and Clinical Trials
Not only has she been a critical consultant, but Dr. Palmer has also led numerous clinical trials focused on MASH and liver diseases, authoring more than 100 publications. Her body of work includes guidelines developed with regulatory authorities, addressing drug-induced liver injury in clinical studies for new therapies targeting liver conditions. Moreover, Dr. Palmer has maintained a medical practice for over two decades, treating liver disease patients.
Future Directions in Liver Health Research
CytoDyn’s leadership, including CEO Dr. Jacob Lalezari, expresses enthusiasm for Dr. Palmer's involvement in the company, emphasizing her unique expertise will enhance CytoDyn's pursuit of groundbreaking treatment options for MASH and liver fibrosis. Dr. Palmer has articulated her excitement about working with CytoDyn, underscoring the transformative potential of new liver disease therapies and the importance of her collaborations with the team.
About CytoDyn
CytoDyn is committed to innovating in the biotechnology sector through the development and commercialization of leronlimab, which targets CCR5—a key protein involved in various disease mechanisms. The company is not only investing in oncology and inflammation but is also looking into various other therapeutic areas, including HIV and liver diseases.
About SMC Laboratories
SMC Laboratories is a contract research organization (CRO) that emphasizes conducting essential non-clinical research for drug development. With a focus on custom study designs, SMC Laboratories specializes in pharmacological studies applicable to inflammation and fibrosis, utilizing innovative mouse models that permit rigorous evaluation of liver cancer linked to metabolic dysfunction.
Frequently Asked Questions
What is Dr. Melissa Palmer's role at CytoDyn?
Dr. Palmer serves as the Lead Consultant in Hepatology, guiding research and development strategies related to liver diseases.
How does CytoDyn plan to advance liver disease treatment?
CytoDyn aims to validate and extend the initial findings from studies involving leronlimab through follow-up research in collaboration with SMC Laboratories.
What is leronlimab?
Leronlimab is an investigational monoclonal antibody that targets CCR5 and is being explored for various therapeutic applications including liver conditions.
Where is CytoDyn located?
CytoDyn is based in Vancouver, Washington, focusing on innovative biotechnology research and development.
What are the expected outcomes of the follow-up studies?
The studies aim to confirm fibrosis reversal in liver conditions and further evaluate the effectiveness of leronlimab combined with other treatments.
